Literature DB >> 14523088

The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.

Jerry P Melchor1, Robert Pawlak, Sidney Strickland.   

Abstract

Accumulation of the amyloid-beta (Abeta) peptide depends on both its generation and clearance. To better define clearance pathways, we have evaluated the role of the tissue plasminogen activator (tPA)-plasmin system in Abeta degradation in vivo. In two different mouse models of Alzheimer's disease, chronically elevated Abeta peptide in the brain correlates with the upregulation of plasminogen activator inhibitor-1 (PAI-1) and inhibition of the tPA-plasmin system. In addition, Abeta injected into the hippocampus of mice lacking either tPA or plasminogen persists, inducing PAI-1 expression and causing activation of microglial cells and neuronal damage. Conversely, Abeta injected into wild-type mice is rapidly cleared and does not cause neuronal degeneration. Thus, the tPA-plasmin proteolytic cascade aids in the clearance of Abeta, and reduced activity of this system may contribute to the progression of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523088      PMCID: PMC6740393     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  84 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Authors:  Manel G Medina; Maria Dolores Ledesma; Jorge E Domínguez; Miguel Medina; Delia Zafra; Francesc Alameda; Carlos G Dotti; Pilar Navarro
Journal:  EMBO J       Date:  2005-04-21       Impact factor: 11.598

3.  Multivariate regression analysis of distance matrices for testing associations between gene expression patterns and related variables.

Authors:  Matthew A Zapala; Nicholas J Schork
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

4.  TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes.

Authors:  Thomas J LaRocca; Andrea Mariani; Linda R Watkins; Christopher D Link
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

Review 5.  Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators.

Authors:  Bruce S McEwen
Journal:  Eur J Pharmacol       Date:  2008-01-30       Impact factor: 4.432

6.  Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.

Authors:  R-M Liu; T van Groen; A Katre; D Cao; I Kadisha; C Ballinger; L Wang; S L Carroll; L Li
Journal:  Neurobiol Aging       Date:  2009-07-14       Impact factor: 4.673

Review 7.  Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism.

Authors:  D Allan Butterfield; Miranda L Bader Lange
Journal:  J Neurochem       Date:  2009-09-23       Impact factor: 5.372

Review 8.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

9.  Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Authors:  Oyinkan Sofola; Fiona Kerr; Iain Rogers; Richard Killick; Hrvoje Augustin; Carina Gandy; Marcus J Allen; John Hardy; Simon Lovestone; Linda Partridge
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

10.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.